TAVI as Therapy of Choice for Aortic Valve Disease in Osteogenesis Imperfecta.
Jan-Philipp MinolTobias ZeusAlexander BlehmVerena VeulemansPublished in: The Journal of heart valve disease (2019)
Osteogenesis imperfecta (OI) is a syndrome that is often associated with dysfunction of the aortic valve. Because of the resultant fragile vessels and impaired hemostasis, surgical therapy to treat OI is challenging. Previous reports have suggested that transcatheter aortic valve implantation (TAVI) might be a suitable treatment for this condition. To the best of the authors' knowledge, the present case is the first to describe a young patient who underwent successful TAVI to treat osteogenesis imperfecta. The proposal of transfemoral TAVI serving as first-line therapy for aortic valve stenosis in patients suffering from osteogenesis imperfect was confirmed.
Keyphrases
- aortic valve
- transcatheter aortic valve implantation
- aortic valve replacement
- transcatheter aortic valve replacement
- aortic stenosis
- end stage renal disease
- ejection fraction
- newly diagnosed
- bone regeneration
- case report
- chronic kidney disease
- peritoneal dialysis
- oxidative stress
- healthcare
- prognostic factors
- mesenchymal stem cells
- drug induced
- heart failure
- combination therapy